SEOUL -- CGBio, a total healthcare provider in South Korea, has unveiled a skin trouble care patch as the first of its microneedle pipeline. Microneedles or microneedle patches are made from a variety of materials ranging from silicon, titanium, stainless steel, and polymers to increase the diffusivity of drugs to the stratum corneum by creating micron-size pores in the skin.
With the launch of its skin trouble care patch named "CGDew Dermaregen," GBio aims to release functional patches for anti-aging care, whitening and blemish care. "Because CGBio's Dermaregen is absorbed directly into the dermal layer of the skin through microneedles, it delivers active ingredients to the skin more efficiently than conventional spreading cosmetics," CEO Yu Hyun-seung said in a statement on November 14.
The patch will be available in the first half of 2023 through the company's esthetic online mall. Yu said his company would develop market-leading products by combining animal and human medicine with microneedles applied with patented techniques.
Other products in the market use separate packaging materials after molding and drying active ingredients, raising concerns about contamination or damage. CGBio said its microneedle product introduced a patented mold packaging technique to increase safety and show excellent efficacy because microneedles go through an integrated "needle-mold" packaging process that directly uses disposable plastic molds as packaging materials.
There is no process of exposing needles to the air. Since the mold is removed just before the patch is attached, CGBio said that active ingredients can be completely delivered to the dermal layer without damage.
Dermaregen contains ingredients such as Eoseongcho (Houttuynia cordata) extract and Zinc PCA which helps reduce antibacterial action and sebum secretion, as well as allantoin and panthenol which have anti-inflammatory and wound healing effects. It is convenient and hygienic because the patch can be picked up and attached to the skin with an enclosed tweezer.
Through the launch of its first microneedle product, CGBio will enter the original development manufacturing (ODM) market. An ODM company designs and manufactures a product, as specified, that is eventually rebranded by another firm for sale. Such companies allow the firm that owns or licenses the brand to produce products without having to engage in the organization or running of a factory.
CGBio is trying to develop cosmetics, medical devices, and medicines using microneedle technology. In April 2022, the company secured a 12.3 percent stake in Daewoong Therapeutics, a bio-venture company that has developed a transdermal drug delivery system using micrometer-sized needles. Daewoong's system is easy to manufacture and has secured physicochemical stability in storage and transportation.
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.